1 documents found
Information × Registration Number 0302U001309, 0101U000886 , R & D reports Title To develop medico-engineering technology for use activated doxorubicin and electromagnetic irradiation on the tumor popup.stage_title Оптимальні фізико-технічні параметри поляризуючої дії електромагнітного випромінювання на механохімічно активований доксорубіцин та розчин електроліту Head Orel V.E., Registration Date 20-02-2002 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of examination - doxorubicin (DR); DNA; lactose; sodium chloride. Objective - to develop physico-technical basis of medico-engineering technology for combine use of mechanochemically activated agent and electromagnetic radiation and study their effect on experimental tumor process. Methods- physico-chemical, statistical. Instruments: micromill MMVE-0,005, spectrophotometer SPECORD M40, chemiluminometer CLM1C-01, multimeter M 3900, analyzer of mechanoemission TRA-3, NMR -spectrometer "Mercury - 300BB", device "Luch-3 CMS -20-3", device VHF, device EHF, ultrathermostat "Type 03 ", microvoltnanoampermeter "F 136", pH-meter 744, thermostat TS-80M-2. A device was developed and experimental test stand for radiation has been done electromagnetic radiation (ER) with a frequencies of 40,68 MHz, 2450 MHz and 60 GHz at temperatures of 370C and 430C initiate d different polarization and depolarization effects in non-activated, mechanochemically activated DR and in their complexes with DNA and rouse si gnificant changes in the intensity of electrochemiluminescence of mechanoactivated sodium chloride. ER with a frequency of 40,68 MHz at a temperature of 370C at 260 nm rouse the most significant changes of optical density of the mechanochemically activated DR and DNA complex at 260 nm. Mechanochemically activation of DR didn't result in chemical shift in 1H NMR -spectra of the drug at a frequency of 300 MHz only change of time T2 relaxation took place. Product Description popup.authors popup.nrat_date 2020-04-02 Close
R & D report
Head: Orel V.E.. To develop medico-engineering technology for use activated doxorubicin and electromagnetic irradiation on the tumor. (popup.stage: Оптимальні фізико-технічні параметри поляризуючої дії електромагнітного випромінювання на механохімічно активований доксорубіцин та розчин електроліту). Ukrainian Research Institute of Oncology and Radiology. № 0302U001309
1 documents found

Updated: 2026-03-18